Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11312770B2 · kind B2 · utility
1Cited by
123References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2018 |
| Grant date | Apr 26, 2022 |
| Priority date | — |
| Expiry date | Aug 18, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to bispecific, heterodimeric checkpoint antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.